Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label vorasidenib plus temozolomide in adults with IDH-mutant grade 4 astrocytoma
MOH_2025-03-30_013997Phase 2Not yet recruiting
- Sponsor
- Servier
- Start
- Jan 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorasidenib and temozolomide in glioma and astrocytoma, sponsored by Servier. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
vorasidenibtemozolomide
03
Conditions
gliomaastrocytoma
Beyond the preview
Go deeper on MOH_2025-03-30_013997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-30_013997.